Hyundai BioLand Co Ltd
KOSDAQ:052260
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 890
5 340
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Hyundai BioLand Co Ltd
Operating Income
Hyundai BioLand Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hyundai BioLand Co Ltd
KOSDAQ:052260
|
Operating Income
â‚©16.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
10%
|
CAGR 10-Years
1%
|
|
|
AmorePacific Corp
KRX:090430
|
Operating Income
â‚©335B
|
CAGR 3-Years
16%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-7%
|
|
|
Amorepacific Group
KRX:002790
|
Operating Income
â‚©363B
|
CAGR 3-Years
19%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-8%
|
|
|
Cosmax Inc
KRX:192820
|
Operating Income
â‚©195.4B
|
CAGR 3-Years
31%
|
CAGR 5-Years
23%
|
CAGR 10-Years
20%
|
|
|
LG H&H Co Ltd
KRX:051900
|
Operating Income
â‚©346.7B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-5%
|
|
|
Kolmar Korea Co Ltd
KRX:161890
|
Operating Income
â‚©223.1B
|
CAGR 3-Years
38%
|
CAGR 5-Years
19%
|
CAGR 10-Years
15%
|
|
Hyundai BioLand Co Ltd
Glance View
HYUNDAI BIOLAND Co., Ltd. engages in the manufacture and sale of pharmaceutical and functional products. The company is headquartered in Cheongju, Chungcheongbuk-Do. The company went IPO on 2001-05-17. The firm operates its business through four segments. The Cosmetic Raw Material segment produces products such as portulaca extracts, ulmus extracts, crinum extracts, hyaluronic acids and arbutins. The Pharmaceutical Ingredient segment manufactures and sells products such as phellodendron extracts, ampelopsis extracts and gardenia extracts and others. The Ingredients for Health Functional Food segment produces and distributes red ginseng extract powders, seaweed powders, glucosamine powders, black garlic extract powders, dandelion extract powders, green tea extracts and others. The Medical Device segment involves in the provision of medical equipment such as tissue engineering products, comprised of biological wound dressings and collagen, as well as diagnostic kits, comprised of rapid kits, serological kits and mask packs.
See Also
What is Hyundai BioLand Co Ltd's Operating Income?
Operating Income
16.7B
KRW
Based on the financial report for Jun 30, 2025, Hyundai BioLand Co Ltd's Operating Income amounts to 16.7B KRW.
What is Hyundai BioLand Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
1%
Over the last year, the Operating Income growth was 63%. The average annual Operating Income growth rates for Hyundai BioLand Co Ltd have been 17% over the past three years , 10% over the past five years , and 1% over the past ten years .